NCT07747506 — "Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)" trial site landscape

Public-registry site landscape for NCT07747506, “Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)”, a Low Grade Ovarian Serous Adenocarcinoma study sponsored by Verastem, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07747506 (registry record)
Study title	Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Official title	Open-Label Extension Study to Provide Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Sponsor	Verastem, Inc.
Condition(s)	Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer
Phase	PHASE2
Listed sites	2
Site countries	France

Patient-friendly overview of this study: eichor.com/study/NCT07747506.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07747506 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →